Phase 3 trial in adults with newly-diagnosed t-AML or AML-MRC
Phase 3 study was a multicenter, open-label, active-controlled, randomized trial of VYXEOS vs 7+3 (cytarabine and daunorubicin) in 309 AML patients (aged 60-75)1,2
AML=acute myeloid leukemia; AML-MRC=acute myeloid leukemia with myelodyplasia-related changes; HSCT=hematopoietic stem cell transplant; PS=performance status; t-AML=therapy-related acute myeloid leukemia.
References: 1. VYXEOS [package insert]. Palo Alto, CA: Jazz Pharmaceuticals. 2. Lancet JE, Uy GL, Cortes JE, et al. Final results of a phase III randomized trial of VYXEOS™ (CPX-351) versus 7 + 3 in older patients with newly diagnosed high-risk (secondary) AML. Oral presentation at: American Society of Clinical Oncology Annual Meeting; June 3-7, 2016; Chicago, IL.
VYXEOS has different dosage recommendations than daunorubicin hydrochloride injection, cytarabine injection, daunorubicin citrate liposome injection, and cytarabine liposome injection. Verify drug name and dose prior to preparation and administration to avoid dosing errors.Important Safety Information